Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256674518> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4256674518 endingPage "33" @default.
- W4256674518 startingPage "29" @default.
- W4256674518 abstract "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of bortezomib for the treatment of multiple myeloma patients at first relapse and beyond, in accordance with the licensed indication, based upon the evidence submission from Ortho Biotech to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The outcomes stated in the manufacturer’s definition of the decision problem were time to disease progression, response rate, survival and quality of life. The literature searches for clinical and cost-effectiveness studies were adequate and the one randomised controlled trial (RCT) included was of reasonable quality. Results from the RCT suggest that bortezomib increases survival and time to disease progression compared with high-dose dexamethasone (HDD) in multiple myeloma patients who have had a relapse after one to three treatments. Cost-effectiveness analysis based on the same trial and an observational study was reasonable and gave an estimated cost per life-year gained of £30,750, which ranged from £27,957 to £36,747 on sensitivity analysis. An attempt was made to replicate the results of the manufacturer’s model and to compare the results to the Kaplan–Meier survival curve presented in the manufacturer’s submission. In addition, a one-way sensitivity analysis and a probabilistic sensitivity analysis were undertaken, as well as additional scenario analyses. Based on these analyses the ERG suggests that the cost-effectiveness results presented in the manufacturer’s submission may underestimate the cost per life-year gained for bortezomib therapy (versus high-dose dexamethasone) when potential UK practice and scenarios are considered. The guidance issued by NICE in June 2006 as a result of the STA states that bortezomib monotherapy for the treatment of relapsed multiple myeloma is clinically effective compared with HDD but has not been shown to be cost-effective and is not recommended for the treatment of progressive multiple myeloma in patients who have received at least one previous therapy and who have undergone, or are unsuitable for, bone marrow transplantation." @default.
- W4256674518 created "2022-05-12" @default.
- W4256674518 creator A5011437367 @default.
- W4256674518 creator A5050159533 @default.
- W4256674518 creator A5069847534 @default.
- W4256674518 creator A5071970432 @default.
- W4256674518 creator A5076758337 @default.
- W4256674518 creator A5080343755 @default.
- W4256674518 creator A5085662334 @default.
- W4256674518 date "2009-06-01" @default.
- W4256674518 modified "2023-10-13" @default.
- W4256674518 title "Bortezomib for the treatment of multiple myeloma patients" @default.
- W4256674518 cites W2089337918 @default.
- W4256674518 cites W2114724178 @default.
- W4256674518 doi "https://doi.org/10.3310/hta13suppl1-05" @default.
- W4256674518 hasPublicationYear "2009" @default.
- W4256674518 type Work @default.
- W4256674518 citedByCount "2" @default.
- W4256674518 countsByYear W42566745182012 @default.
- W4256674518 countsByYear W42566745182018 @default.
- W4256674518 crossrefType "journal-article" @default.
- W4256674518 hasAuthorship W4256674518A5011437367 @default.
- W4256674518 hasAuthorship W4256674518A5050159533 @default.
- W4256674518 hasAuthorship W4256674518A5069847534 @default.
- W4256674518 hasAuthorship W4256674518A5071970432 @default.
- W4256674518 hasAuthorship W4256674518A5076758337 @default.
- W4256674518 hasAuthorship W4256674518A5080343755 @default.
- W4256674518 hasAuthorship W4256674518A5085662334 @default.
- W4256674518 hasBestOaLocation W42566745181 @default.
- W4256674518 hasConcept C112930515 @default.
- W4256674518 hasConcept C126322002 @default.
- W4256674518 hasConcept C143998085 @default.
- W4256674518 hasConcept C159110408 @default.
- W4256674518 hasConcept C168563851 @default.
- W4256674518 hasConcept C177713679 @default.
- W4256674518 hasConcept C19527891 @default.
- W4256674518 hasConcept C199360897 @default.
- W4256674518 hasConcept C23131810 @default.
- W4256674518 hasConcept C2776364478 @default.
- W4256674518 hasConcept C2777478702 @default.
- W4256674518 hasConcept C2779256446 @default.
- W4256674518 hasConcept C2779951463 @default.
- W4256674518 hasConcept C3019080777 @default.
- W4256674518 hasConcept C41008148 @default.
- W4256674518 hasConcept C535046627 @default.
- W4256674518 hasConcept C64332521 @default.
- W4256674518 hasConcept C71924100 @default.
- W4256674518 hasConceptScore W4256674518C112930515 @default.
- W4256674518 hasConceptScore W4256674518C126322002 @default.
- W4256674518 hasConceptScore W4256674518C143998085 @default.
- W4256674518 hasConceptScore W4256674518C159110408 @default.
- W4256674518 hasConceptScore W4256674518C168563851 @default.
- W4256674518 hasConceptScore W4256674518C177713679 @default.
- W4256674518 hasConceptScore W4256674518C19527891 @default.
- W4256674518 hasConceptScore W4256674518C199360897 @default.
- W4256674518 hasConceptScore W4256674518C23131810 @default.
- W4256674518 hasConceptScore W4256674518C2776364478 @default.
- W4256674518 hasConceptScore W4256674518C2777478702 @default.
- W4256674518 hasConceptScore W4256674518C2779256446 @default.
- W4256674518 hasConceptScore W4256674518C2779951463 @default.
- W4256674518 hasConceptScore W4256674518C3019080777 @default.
- W4256674518 hasConceptScore W4256674518C41008148 @default.
- W4256674518 hasConceptScore W4256674518C535046627 @default.
- W4256674518 hasConceptScore W4256674518C64332521 @default.
- W4256674518 hasConceptScore W4256674518C71924100 @default.
- W4256674518 hasFunder F4320334661 @default.
- W4256674518 hasIssue "Suppl 1" @default.
- W4256674518 hasLocation W42566745181 @default.
- W4256674518 hasLocation W42566745182 @default.
- W4256674518 hasLocation W42566745183 @default.
- W4256674518 hasOpenAccess W4256674518 @default.
- W4256674518 hasPrimaryLocation W42566745181 @default.
- W4256674518 hasRelatedWork W10535914 @default.
- W4256674518 hasRelatedWork W12101965 @default.
- W4256674518 hasRelatedWork W12291014 @default.
- W4256674518 hasRelatedWork W17271954 @default.
- W4256674518 hasRelatedWork W17591755 @default.
- W4256674518 hasRelatedWork W22184081 @default.
- W4256674518 hasRelatedWork W2594600 @default.
- W4256674518 hasRelatedWork W3519569 @default.
- W4256674518 hasRelatedWork W8015672 @default.
- W4256674518 hasRelatedWork W17299077 @default.
- W4256674518 hasVolume "13" @default.
- W4256674518 isParatext "false" @default.
- W4256674518 isRetracted "false" @default.
- W4256674518 workType "article" @default.